Another prediction. No one trust Misleading, he has such weak image in market. PR was Misleading style, no meat, data will be presented in another pilgrimage which might be another 12month. I won't be surprise if this comes down to sub 4 level in a week or so.
The intentions and mechanisms regarding a BP buyout of Anavex are unknown to me. Nonetheless, both PB executives and scientists now know for sure that Anavex will be able to play in the CNS treatment game, even better than with the BP ...mabs immunoactives. In a few years (2023?), BP drugs are going to have a hard time competing with those of Anavex Life Sciences Corp.